Ovarian Cancer Market Report 2026

The ovarian cancer market size has grown rapidly in recent years. It will grow from $4.35 billion in 2025 to $5.15 billion in 2026 at a compound annual growth rate (CAGR) of 18.5%. The growth in the historic period can be attributed to limited treatment options in early years, high mortality due to late-stage diagnosis, adoption of conventional chemotherapy and surgery, rising prevalence of ovarian cancer globally, growing awareness about women’s health and gynecological cancers.

The ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $10.02 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to increasing adoption of targeted therapy and immunotherapy, expansion of personalized medicine and genomic profiling, rising use of minimally invasive surgical techniques, growing awareness and early detection programs, increasing investment in ovarian cancer research and diagnostics. Major trends in the forecast period include rising adoption of targeted therapy and immunotherapy, increasing focus on early diagnosis and screening programs, growing use of minimally invasive surgical techniques, expansion of personalized medicine and genomic profiling, increasing awareness about ovarian cancer risk factors.

The growing female population is expected to drive growth in the ovarian cancer market in the coming years. The female population refers to the total number of women living in a region or worldwide at a specific time. Factors such as increased life expectancy, improved healthcare, and demographic shifts contribute to this rise. Ovarian cancer treatments support women by providing surgery, chemotherapy, targeted therapy, and immunotherapy to remove cancerous cells, slow disease progression, relieve symptoms, improve survival rates, and enhance overall quality of life. For instance, in July 2023, the UN Division for Inclusive Social Development reported that women and girls accounted for approximately 49.7 percent of the global population. Therefore, the increasing female population is propelling growth in the ovarian cancer market.

Companies in the ovarian cancer market are focusing on advanced AI-driven solutions to improve early detection and patient care. AI platforms for ovarian cancer integrate machine learning, medical imaging, genomic data, electronic health records, and real-time analytics to support early diagnosis, personalized treatment planning, and patient monitoring. For example, in February 2024, AIIMS Delhi, in collaboration with CDAC Pune, launched iOncology.ai, an indigenously developed AI platform for early detection of breast and ovarian cancer. The platform uses deep learning models to analyze radiological and histopathological images with high accuracy, aiming to improve early diagnosis and survival rates. It is deployed in multiple hospitals, providing risk assessments, recommending mammograms - especially for women in rural areas - and integrating into the broader healthcare system to reduce strain on medical services.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition strengthens AbbVie’s oncology portfolio by integrating ImmunoGen’s antibody-drug conjugate, ELAHERE, alongside other promising cancer therapies. ImmunoGen Inc., based in the US, specializes in developing antibody-drug conjugates (ADCs) for the treatment of ovarian cancer.

Major companies operating in the ovarian cancer market are Pfizer Incorporated, Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Bristol‑Myers Squibb Company, Boehringer Ingelheim GmbH, Clovis Oncology Inc., Novogen Limited, Oasmia Pharmaceutical AB, Aeterna Zentaris Inc., Allarity Therapeutics Inc., Daiichi Sankyo Inc., Astellas Pharma Inc., Jiangsu HengRui Medicine Co Ltd, ImmunoGen Inc., Verastem Oncology Inc., Sutro Biopharma Inc., Mersana Therapeutics Inc.

North America was the largest region in the ovarian cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the ovarian cancer market by influencing the cost and availability of imported chemotherapy drugs, targeted therapy agents, diagnostic equipment, and surgical instruments. Hospitals, diagnostic centers, and pharmacies in regions such as north america, europe, and asia-pacific are most affected due to reliance on imported products. This has led to higher treatment costs and occasional delays in therapy delivery. However, tariffs have also encouraged domestic manufacturing, stimulated local production of therapies and equipment, and promoted resilience in regional supply chains.

The ovarian cancer market research report is one of a series of new reports that provides ovarian cancer market statistics, including ovarian cancer industry global market size, regional shares, competitors with a ovarian cancer market share, detailed ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer industry. This ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ovarian cancer is a type of cancer that develops in the ovaries, the female reproductive organs responsible for producing eggs (ova) and hormones like estrogen and progesterone. It can arise in different parts of the ovaries, including the surface epithelium, germ cells, or stroma.

The main types of ovarian cancer include epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. Epithelial ovarian tumors originate in the epithelial cells forming the outer lining of the ovaries. Treatment options include chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. These treatments are administered via oral, parenteral, and other routes and are used by end users such as hospitals, diagnostic centers, drug stores, online pharmacies, and others.

The ovarian cancer market consists of revenues earned by entities by providing services such as screening and early detection services, diagnostic imaging services, surgical treatment services, clinical trial services, and palliative and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer market also includes sales of taxane-based chemotherapy, surgical treatment devices, radiation therapy equipment, angiogenesis inhibitors, and checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.